Transient increment of HTLV-2 proviral load in HIV-1- coinfected patients during treatment intensification with raltegravir


J Clin Virol. 2014, Mar;59(3):204-7.



Numerous studies have analyzed the effects of raltegravir intensification on HIV-1 viral replication in infected individuals receiving suppressive combined antiretroviral treatment (cART). Nevertheless, there are only two studies on the effect of raltegravir in HTLV-1 infection, and none in HTLV-2.



To study the effect of raltegravir on HTLV-2 infection in HIV-1-co-infected individuals.


Study design

This retrospective longitudinal study included four HTLV-2-HIV-1-co-infected individuals who received raltegravir-based cART during 48 weeks and 11 HTLV-2-HIV-1-co-infected individuals under cART without raltegravir during 48 weeks. HTLV-2 proviral load, CD4 and CD8 count and frequency were analyzed.



HTLV-2 proviral load significantly increased at week 24 compared to baseline among all the patients who received raltegravir (p = 0.003), while no significant increases were found in the control group. No significant variation in either CD8 or CD4 counts was found during the follow up in both groups.



Raltegravir induced a transient increment on total HTLV-2 DNA proviral load in HTLV-2/HIV-1-coinfected individuals on suppressive cART after 24 weeks.


Read abstract online

Abad-Fernández M, Cabrera C, García E, Vallejo A.

See author affiliations

Grupos de IrsiCaixa vinculados: Virología Tisular (VITI)